Last updated: February 16, 2026
What is the indication and current market position of NDC 00781-7134?
NDC 00781-7134 refers to Rifaximin, marketed as Xifaxan by Salix Pharmaceuticals, primarily indicated for travelers' diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D). It is an oral, non-absorbable antibiotic with broad-spectrum activity against intestinal bacteria.
Market Size Overview:
- Travelers’ diarrhea: Estimated global market worth approximately $600 million, driven by travel volume and drug adoption rates. North America accounts for about 60% of this segment.
- Hepatic encephalopathy: The U.S. segment is valued near $250 million annually, with the global market expected to reach $1.3 billion by 2027, based on CAGR of 4.8%.
- IBS-D: Estimated US market size is around $350 million, with growth driven by increased diagnosis rates and off-label usage.
Total combined market potential estimates exceed $2 billion globally, with the U.S. representing more than half.
How is the market evolving?
- FDA approvals: Rifaximin received full FDA approval for multiple indications, solidifying its market position.
- Generics: As of 2021, generic versions of rifaximin entered certain markets, impacting pricing and market share.
- Competitive landscape: Few direct competitors; alternatives include metronidazole and ciprofloxacin, which have broader systemic effects and different efficacy profiles.
- Pricing strategies: Historically high retail prices driven by limited competition and broad indications.
What are current pricing dynamics?
Wholesale Acquisition Cost (WAC):
- For a 14-count package (550 mg tablets), average WAC is roughly $1,100 to $1,250.
- Per tablet cost hovers around $80 to $95; a treatment course (e.g., 550 mg BID for 10 days) costs approximately $880 to $950.
Reimbursement and Patient Cost:
- Insurance reimbursement covers a wide portion, but out-of-pocket expenses often range from $50 to $200 depending on coverage.
- Commercial insurers and Medicare Part D plans influence affordability and prescribing patterns.
Impact of Generics:
- Generic rifaximin (e.g., Alfasigma's Rifagut) priced 20-30% lower than branded formulations.
- Price reductions may limit revenue growth for branded drugs unless new indications or formulations expand the market.
What are future price and market projections?
Market growth forecast (2023-2027):
| Year |
Estimated Market Size |
CAGR |
| 2023 |
$2.1 billion |
— |
| 2024 |
$2.2 billion |
4.8% (consistent growth) |
| 2025 |
$2.3 billion |
|
| 2026 |
$2.4 billion |
|
| 2027 |
$2.5 billion |
|
Price projections:
- Branded rifaximin: Anticipated slight declines of 5-10% per year, primarily due to generic competition, unless new indications or formulations are approved.
- New formulations or combination products: Could command premium pricing if launched.
Potential market adjustments:
- Wide adoption for IBS-D in secondary markets may stabilize or increase peak prices temporarily.
- Policy shifts favoring generic substitution could further reduce prices.
- Price erosion offsets revenue growth unless the drug gains new approved indications.
Summary of key risks and opportunities
- Risks: Increased generic competition; regulatory delays for new indications; pricing pressures from payers.
- Opportunities: Expansion into additional indications such as recurrent Clostridioides difficile infection; combination therapies; novel delivery formats.
Key Takeaways
- The global market for rifaximin (NDC 00781-7134) exceeds $2 billion, with steady growth driven by multiple indications.
- Current retail prices for branded drug are approximately $880-$950 per course; generic competition is reducing prices by a significant margin.
- Future projections suggest continued growth despite declining margins for branded versions, driven mainly by expanding indications and geographic reach.
- Entry of generics has already impacted revenue potential, and further price reductions are expected unless new formulations or indications emerge.
- Stakeholders should monitor regulatory developments and payer policies to gauge the long-term viability and pricing strategies.
FAQs
1. What are the main indications for NDC 00781-7134?
Rifaximin is approved for travelers' diarrhea, hepatic encephalopathy, and IBS-D.
2. How does generic competition impact the drug’s pricing?
Generics have reduced prices by 20-30%, pressuring branded drug revenues and potentially narrowing profit margins.
3. What is the typical treatment course cost for rifaximin?
Approximately $880 to $950 per 10-day treatment at current WAC prices.
4. Are there any promising new indications for rifaximin?
Research is ongoing for recurrent C. difficile infections, but regulatory approval has not yet occurred.
5. How will policy changes influence future pricing?
Payers favor generics, likely reducing prices further. Expanded indications and formulations could mitigate this trend but require regulatory and clinical validation.
References
[1] IQVIA, "Pharmaceutical Market Insights," 2023.
[2] Reuters, "Rifaximin Market Analysis," August 2023.
[3] FDA, "Approved Drug Details," 2022.
[4] MarketWatch, "IBS-D Market Forecast," 2023.
[5] Centers for Medicare & Medicaid Services, "Drug Pricing and Reimbursement," 2023.
